drugset / Trial / NCT06616532
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
Timeline
- Start
- 2024-11-13
- Primary completion
- 2027-01-25
- Completion
- 2028-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |
| Comparator | Topotecan | Small molecule | 1.25 mg/m2 | Intravenous |